CRISPRi Repressor Fusion Peptides for Gene Silencing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current CRISPR interference systems face limitations such as incomplete gene knockdown, sgRNA sequence-dependent repression activity, and variable performance across human cancer cell lines, hindering efficient gene expression control in biological studies and gene therapy applications.

Innovation Solution

A CRISPR interference system comprising a single guide RNA (sgRNA) and a catalytically inactive nuclease operably fused to a repressor fusion peptide, where the repressor fusion peptide includes multiple domains like KOX1, KRBOX1, ZIM3, MAX, MeCP2, and others, enhancing gene silencing efficiency and reducing variability across cell lines.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a dCas9 nuclease is fused to a repressor protein to decrease gene expression, then gene silencing capability is achieved, but gene knockdown completeness is insufficient

Engineering Contradiction:

Improvegene silencing capabilityVSAvoidgene knockdown completeness

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent combines multiple repressor domains (KRAB, MeCP2, SIM, PRC2) into a single repressor fusion peptide that is operably fused to the dCas9 nuclease. This merging of multiple functional domains into one integrated repressor complex enhances the completeness of gene knockdown while maintaining the targeted silencing capability, directly resolving the contradiction between achieving gene silencing and ensuring knockdown completeness.

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If a repressor protein is used to shut down gene expression, then gene silencing is achieved, but repression activity becomes sgRNA sequence-dependent

Engineering Contradiction:

Improvegene silencing effectivenessVSAvoidrepression activity consistency

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The repressor fusion peptide is constructed as a composite of multiple repressor domains (KRAB, MeCP2, SIM, PRC2) that work synergistically. This composite structure provides consistent repression activity across different sgRNA sequences by combining multiple mechanisms of transcriptional repression, thereby reducing sgRNA sequence-dependency while maintaining effective gene silencing.

Inventive Principle:

Principle #40Composite materials

3Ease of operation

If a CRISPRi system is implemented to control gene expression, then gene regulation capability is achieved, but performance varies across human cancer cell lines

Engineering Contradiction:

Improvegene expression control capabilityVSAvoidperformance consistency across cell lines

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The repressor fusion peptide incorporates multiple repressor domains with different mechanisms of action (KRAB for heterochromatin formation, MeCP2 for DNA methylation recruitment, SIM for chromatin interaction, PRC2 for histone modification). This multi-functional design enables the CRISPRi system to achieve consistent gene knockdown performance across diverse human cancer cell lines by providing multiple pathways for transcriptional repression that can adapt to different cellular contexts.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20240158793A1Repressor proteins for gene regulation and crispr interference

Publication Date: 2024.05.16 GEORGIA TECH RES CORP

AI summary

The present disclosure relates to CRISPR interference (CRISPRi) systems and uses thereof.